Isis VP-Corporate Development Kate Winkler Corcoran: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Corcoran discusses firm’s strategy to license and develop specific targets developed through Isis’ proprietary RNA antisense technology.
You may also be interested in...
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?